Vidipha Central Pharmaceutical JSC (VDP) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Flat results in Jun 25

ROCE(HY) Lowest at 9.13%
INVENTORY TURNOVER RATIO(HY) Lowest at 1.98%
OPERATING PROFIT(Q) Lowest at VND 19,971.44 MM

With ROE of 9.08%, it has a fair valuation with a 0.00 Price to Book Value

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

VND Million (Small Cap)

P/E

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.15

Return on Equity

8.28%

Price to Book

0.00

Revenue and Profits:

Net Sales:

225,110 Million

(Quarterly Results - Jun 2025)

Net Profit:

12,555 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

0.0%

6 Months

30.56%

1 Year

34.29%

2 Years

48.42%

3 Years

49.6%

4 Years

52.02%

5 Years

74.61%

Vidipha Central Pharmaceutical JSC for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

11.58%

EBIT Growth (5y)

10.05%

EBIT to Interest (avg)

4.71

Debt to EBITDA (avg)

0.68

Net Debt to Equity (avg)

-0.20

Sales to Capital Employed (avg)

1.00

Tax Ratio

20.61%

Dividend Payout Ratio

76.87%

Pledged Shares

Institutional Holding

ROCE (avg)

11.37%

ROE (avg)

10.13%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

EV to EBIT

-1.43

EV to EBITDA

-1.03

EV to Capital Employed

-0.18

EV to Sales

-0.12

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

9.08%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Mildly Bullish

Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

Bearish

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -0.15% vs -8.27% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -19.71% vs -43.27% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "225,110.20",
          "val2": "225,458.60",
          "chgp": "-0.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "19,971.40",
          "val2": "24,413.90",
          "chgp": "-18.20%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "2,485.20",
          "val2": "2,879.50",
          "chgp": "-13.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "12,554.50",
          "val2": "15,636.30",
          "chgp": "-19.71%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "73.40%",
          "val2": "91.10%",
          "chgp": "-1.77%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -8.32% vs 1.14% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -10.47% vs 18.55% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "934,486.80",
          "val2": "1,019,316.70",
          "chgp": "-8.32%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "112,234.30",
          "val2": "126,749.30",
          "chgp": "-11.45%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "14,848.80",
          "val2": "27,558.60",
          "chgp": "-46.12%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "71,823.20",
          "val2": "80,218.80",
          "chgp": "-10.47%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "87.60%",
          "val2": "97.30%",
          "chgp": "-0.97%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

225,110.20

225,458.60

-0.15%

Operating Profit (PBDIT) excl Other Income

19,971.40

24,413.90

-18.20%

Interest

2,485.20

2,879.50

-13.69%

Exceptional Items

0.00

Consolidate Net Profit

12,554.50

15,636.30

-19.71%

Operating Profit Margin (Excl OI)

73.40%

91.10%

-1.77%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is -0.15% vs -8.27% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -19.71% vs -43.27% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

934,486.80

1,019,316.70

-8.32%

Operating Profit (PBDIT) excl Other Income

112,234.30

126,749.30

-11.45%

Interest

14,848.80

27,558.60

-46.12%

Exceptional Items

0.00

Consolidate Net Profit

71,823.20

80,218.80

-10.47%

Operating Profit Margin (Excl OI)

87.60%

97.30%

-0.97%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -8.32% vs 1.14% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -10.47% vs 18.55% in Dec 2023

All Annual Results

Company CV

About Vidipha Central Pharmaceutical JSC

Vidipha Central Pharmaceutical JSC

Pharmaceuticals & Biotechnology

Vidipha Central Pharmaceutical Joint - Stock Company is a Vietnam-based company primarily engaged in the pharmaceuticals sector. The Company's leading business activity is the manufacture of pharmaceuticals in various forms, such as tablet, liquid, powder and ointment. The Company's products include antibiotics, anti-inflammatory drugs, vitamins, minerals, pain killers, antipyretics and antihistamines, among others.

Company Coordinates

Company Details

184/2 Le Van Sy , HO CHI MINH None : None

Tel: 84 8 38440448

http://www.vidipha.com.vn/

Registrar Details